Relief Therapeutics Holding AG (SWX:RLF) entered into a Asset Purchase Agreement to acquire ZYESAMI of NRx Pharmaceuticals, Inc. for $13 million on November 12, 2022. Relief will pay NeuroRx milestone payments if it can successfully obtain commercial approval of an aviptadil product $13 million. Relief will pay NeuroRx royalties based on a percentage of future sales of an aviptadil product up to a maximum of $30 million in the aggregate.

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc. on December 20, 2022.